Recombinant vector for improving yield of monensin, primer group, construction method, engineering bacterium and application
By heterologously overexpressing the pcc and ccr genes of Streptocytica albicans in Streptocytica, and using recombinant vectors to improve the expression of monenectin synthesis precursors, the cost and titer response of increased precursor supply in the prior art is solved. The impact problem has achieved a significant increase in monenzyme production.
Patent Information
- Application Number
- CN202411312999.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-29
AI Technical Summary
In the existing monenectin production, the method of increasing the supply of synthetic precursors to increase the yield will increase the production cost and will have an impact on the pH value of the fermentation broth and affect the titer.
By designing a recombinant vector containing yccc and yccr genes and corresponding promoters, the recombinant vector was constructed using Gibson assembly method, and heterologously overexpressed the pcc gene and ccr gene of Streptococcus albicans to Streptococcus cinnamon to improve monenectin synthesis The expression of precursors can increase monenectin production.
The production of monenectin can be increased, the production costs and the production efficiency can be improved without increasing the supply of synthetic precursors. The production of monenectin can be increased by 11% to 38%.
Smart Images

Figure CN119040369A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene engineering technology, and in particular to a recombinant vector, a primer set, a construction method, an engineering bacterium and an application thereof for improving the yield of monensin. Background Art
[0002] The main active ingredient of monensin is monensin A, which is a polyether antibiotic widely used in animal husbandry. It is often used as an anticoccidial agent for poultry and a growth-promoting feed additive for ruminants. In recent years, studies have shown that monensin also plays a very positive role in anti-tumor effects. Improving the production of monensin has important application value and economic significance.
[0003] Streptomyces cinnamonensis is an industrial producer of monensin. Monensin is a typical polyketide unit, and its synthetic precursors are acetyl CoA, methylmalonyl CoA and ethylmalonyl CoA. Among them, the former serves as the starting unit, and the latter two serve as extension units. In Streptomyces, the synthesis of secondary metabolites is closely related to the supply of precursors produced by primary metabolism, and the supply of precursors often becomes the rate-limiting factor for the synthesis of secondary metabolites. In production, the supply of precursors can be appropriately increased by feeding, but it will increase production costs and easily affect the pH of the fermentation broth, thereby affecting the increase in potency. Summary of the invention
[0004] In order to solve the above problems, the present invention provides a recombinant vector, a primer set, a construction method, an engineered bacterium and an application for increasing the yield of monensin. The recombinant vector provided by the present invention can increase the yield of monensin without increasing the supply of precursors, thereby reducing production costs and improving production efficiency.
[0005] In order to achieve the above object, the present invention provides the following technical solutions:
[0006] The invention provides a recombinant vector for improving the yield of monensin, comprising a starting vector and a recombinant gene inserted into the starting vector; the recombinant gene comprises a target gene and a promoter; the target gene comprises a ypcc gene and / or a yccr gene; the ypcc gene comprises a ypcc-1 gene and a ypcc-2 gene; the promoter comprises one or more of a Psco7677 promoter, a Pkasop* promoter and a Ppkn5 promoter; the nucleotide sequence of the ypcc-1 gene is shown in SEQ ID No.1; the nucleotide sequence of the ypcc-2 gene is shown in SEQ ID No.2; the nucleotide sequence of the Psco7677 promoter is shown in SEQ ID No.3; the nucleotide sequence of the Pkasop* promoter is shown in SEQ ID No.4; the nucleotide sequence of the Ppkn5 promoter is shown in SEQ ID No.5; and the nucleotide sequence of the yccr gene is shown in SEQ ID No.6.
[0007] Preferably, the starting vector comprises a pSET152 vector.
[0008] Preferably, the recombinant gene includes any one of 1) to 7), specifically:
[0009] 1) Psco7677 promoter, ypcc-1 gene and ypcc-2 gene linked in sequence from 5' to 3' direction;
[0010] 2) Pkasop* promoter, ypcc-1 gene and ypcc-2 gene connected in sequence from 5' to 3' direction;
[0011] 3) Ppkn5 promoter, ypcc-1 gene and ypcc-2 gene connected in sequence from 5' to 3' direction;
[0012] 4) Psco7677 promoter and yccr gene linked sequentially in the 5' to 3' direction;
[0013] 5) Pkasop* promoter and yccr gene linked sequentially from 5' to 3' end;
[0014] 6) Ppkn5 promoter and yccr gene linked sequentially in the 5' to 3' direction;
[0015] 7) Psco7677 promoter, ypcc-1 gene, ypcc-2 gene, Pkasop* promoter and yccr gene are sequentially connected from 5' to 3' end.
[0016] Preferably, when the recombinant gene is any one of 1) to 6), the recombinant gene is located between the BamH I and Xba I restriction sites of the pSET152 vector; when the recombinant gene is 7), the recombinant gene is located between the BamH I and EcoR I restriction sites of the pSET152 vector.
[0017] The present invention provides a primer set for constructing the recombinant vector described in the above technical solution, wherein the primer set includes one or more of the first primer set to the seventh primer set, specifically:
[0018] The first primer set included: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, and ypcc1-Psco7677-R;
[0019] The second primer set included: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Pkasop*-F, and ypcc1-Pkasop*-R;
[0020] The third primer set includes: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Ppkn5-F and ypcc1-Ppkn5-R;
[0021] The fourth primer set includes: yccr-F, 152-yccr-R, 152-Psco7677-F and yccr-Psco7677-R;
[0022] The fifth primer set includes: yccr-F, 152-yccr-R, 152-Pkasop*-F and yccr-Pkasop*-R;
[0023] The sixth primer set includes: yccr-F, 152-yccr-R, 152-Ppkn5-F and yccr-Ppkn5-R;
[0024] The seventh primer set includes: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, ypcc1-Psco7677-R, yccr-F, 152-yccr-R, 152-Pkasop*-F, yccr-Pkasop*-R, Pkasop*-yccr-F and Pkasop*-yccr-R;
[0025] The nucleotide sequences of the ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, ypcc1-Psco7677-R, 152-Pkasop*-F, ypcc1-Pkasop*-R, 152-Ppkn5-F, ypcc1-Ppkn5-R, yccr-F, 152-yccr-R, Pkasop*-yccr-F, Pkasop*-yccr-R, yccr-Psco7677-R, yccr-Pkasop*-R and yccr-Ppkn5-R are shown in SEQ ID No.7 to SEQ ID No.23 respectively.
[0026] The present invention provides a method for constructing the recombinant vector described in the above technical solution using the primer set described in the above technical solution, comprising the following steps:
[0027] Using the sequence shown in SEQ ID No. 1 as a template and ypcc1-F and ypcc1-R as primers, PCR amplification was performed to obtain the ypcc1 fragment;
[0028] Using the sequence shown in SEQ ID No. 2 as a template and ypcc2-F and 152-ypcc2-R as primers, PCR amplification was performed to obtain the ypcc2 fragment;
[0029] Using the sequence shown in SEQ ID No. 3 as a template and 152-Psco7677-F and ypcc1-Psco7677-R as primers, PCR amplification was performed to obtain the first Psco7677 fragment;
[0030] Using the sequence shown in SEQ ID No. 4 as a template and 152-Pkasop*-F and ypcc1-Pkasop*-R as primers, PCR amplification was performed to obtain the first Pkasop* fragment;
[0031] Using the sequence shown in SEQ ID No. 5 as a template and 152-Ppkn5-F and ypcc1-Ppkn5-R as primers, PCR amplification was performed to obtain the first Ppkn5 fragment;
[0032] Using the sequence shown in SEQ ID No. 3 as a template and 152-Psco7677-F and yccr-Psco7677-R as primers, PCR amplification was performed to obtain a second Psco7677 fragment;
[0033] Using the sequence shown in SEQ ID No. 4 as a template and 152-Pkasop*-F and yccr-Pkasop*-R as primers, PCR amplification was performed to obtain a second Pkasop* fragment;
[0034] Using the sequence shown in SEQ ID No. 5 as a template and 152-Ppkn5-F and yccr-Ppkn5-R as primers, PCR amplification was performed to obtain a second Ppkn5 fragment;
[0035] Using the sequence shown in SEQ ID No. 6 as a template and yccr-F and 152-yccr-R as primers, PCR amplification was performed to obtain the yccr fragment;
[0036] The first Psco7677 fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a first recombinant vector;
[0037] The first Pkasop* fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a second recombinant vector;
[0038] The first Ppkn5 fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a third recombinant vector;
[0039] The second Psco7677 fragment and the yccr fragment are inserted into the starting vector using the Gibson assembly method to obtain a fourth recombinant vector;
[0040] The second Pkasop* fragment and the yccr fragment are inserted into the starting vector by using the Gibson assembly method to obtain a fifth recombinant vector;
[0041] The second Ppkn5 fragment and the yccr fragment are inserted into the starting vector by using the Gibson assembly method to obtain a sixth recombinant vector;
[0042] The Psco7677 fragment, the ypcc1 fragment, the ypcc2 fragment, the Pkasop* fragment and the yccr fragment were inserted into the starting vector using the Gibson assembly method to obtain the seventh recombinant vector.
[0043] Preferably, the construction method of the seventh recombinant vector is: using the fifth recombinant vector as a template and Pkasop*-yccr-F and Pkasop*-yccr-R as primers, amplifying to obtain a Pkasop*-yccr fragment; and inserting the Pkasop*-yccr fragment between the BamH I and EcoR I restriction sites of the first recombinant vector by the Gibson assembly method to obtain the seventh recombinant vector.
[0044] The present invention provides an engineered bacterium, which comprises: the recombinant vector described in the above technical solution, or a recombinant vector constructed using the primer set described in the above technical solution, or a recombinant vector constructed using the method described in the above technical solution.
[0045] Preferably, the starting strain of the engineered bacteria includes Streptomyces cinnamonensis.
[0046] The present invention provides the use of the recombinant vector described in the above technical solution, or the recombinant vector constructed using the primer set described in the above technical solution, or the recombinant vector constructed using the method described in the above technical solution, or the recombinant bacteria described in the above technical solution in improving the yield of monensin.
[0047] Beneficial effects:
[0048] The invention provides a recombinant vector for improving the yield of monensin, comprising a starting vector and a recombinant gene inserted into the starting vector; the recombinant gene comprises a target gene and a promoter; the target gene comprises a ypcc gene and / or a yccr gene; the ypcc gene comprises a ypcc-1 gene and a ypcc-2 gene; the promoter comprises one or more of a Psco7677 promoter, a Pkasop* promoter and a Ppkn5 promoter; the nucleotide sequence of the ypcc-1 gene is shown in SEQ ID No.1; the nucleotide sequence of the ypcc-2 gene is shown in SEQ ID No.2; the nucleotide sequence of the Psco7677 promoter is shown in SEQ ID No.3; the nucleotide sequence of the Pkasop* promoter is shown in SEQ ID No.4; the nucleotide sequence of the Ppkn5 promoter is shown in SEQ ID No.5; and the nucleotide sequence of the yccr gene is shown in SEQ ID No.6. The recombinant vector provided by the present invention heterologously overexpresses the pcc gene and / or ccr gene of Streptomyces albus into Streptomyces cinnamomi through a suitable promoter, and transforms the Streptomyces cinnamomi at the gene level, so that the transformed Streptomyces cinnamomi overexpresses the synthetic precursors (methylmalonyl CoA and ethylmalonyl CoA) of monensin, and the yield of monensin can be increased without increasing the supply of the precursors, thereby reducing the production cost and improving the production efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0050] Figure 1 The PCR electrophoresis results of different engineered bacteria are shown in Figure 1, where the electrophoresis band in the box is 741 bp;
[0051] Figure 2 The fermentation yield of monensin by different engineered bacteria. DETAILED DESCRIPTION
[0052] The present invention provides a recombinant vector for improving the yield of monensin, comprising a starting vector and a recombinant gene inserted into the starting vector; the recombinant gene comprises a target gene and a promoter; the target gene comprises a ypcc gene and / or a yccr gene; the ypcc gene comprises a ypcc-1 gene and a ypcc-2 gene; the promoter comprises one or more of a Psco7677 promoter, a Pkasop* promoter and a Ppkn5 promoter; the nucleotide sequence of the ypcc-1 gene is shown in SEQ ID No.1; the nucleotide sequence of the ypcc-2 gene is shown in SEQ ID No.2; the nucleotide sequence of the Psco7677 promoter is shown in SEQ ID No.3; the nucleotide sequence of the Pkasop* promoter is shown in SEQ ID No.4; the nucleotide sequence of the Ppkn5 promoter is shown in SEQ ID No.5; the nucleotide sequence of the yccr gene is shown in SEQ ID No.6, and the specific sequences are as follows:
[0053] SEQ ID No.1:
[0054]
[0055] SEQ ID No.2:
[0056]
[0057] SEQ ID No.3:
[0058] 5’-ccggaaccctcccgaagccgtcgtccccggtcggggagagtattggtgcgcggcaatggttgaagatgaatgtcgttttctattaac gtctgaccatcgcgtgtcggccgcgcccgcggccgcaggggaggggccctcatgaccttggcaggccaggcgttcggagccgggagagtcggcgccgagcgggaccggtgtgtcggggcggggcagtgcgtcctcgccgcgccgggtgtcttcgaccaggacgaggaggacgggctcgtgcgcgtcctcgccgagaggccctccgcggccgagtcggacgccgtgcgcgcggccgtgcgggcctgcccgtctggagcgctcactcttcggtagcccccgcgggccgtccctcttccggccccccgcctcgcccaccgcctcacttcacgcgccgcaggtgtcccgcggcgcggttcagctcagcagaacgtcaaggagaagccgagcaacggaggtacggac-3’;
[0059] SEQ ID No.4:
[0060] 5’-ggggtcagcaccgtttctgcggactggctttctacgtgttccgcttcctttagcagcccttgcgccctgagtgcttgcggcagcgtgat gttcacattcgaaccgtctctgctttgacaacatgctgtgcggtgttgtaaagtcgtggcccgtgcaggactgggggagtt-3’;
[0061] SEQ ID No.5:
[0062] 5’-ggcagcggcctcccggcgctcggcacggttcgcggacggcgcatgagtacccgccgcgaaggggcggaatcaccttccgccc ggccgtacggccggaagggttcccgagcggcacaaggtcccggagatccggtgcggccggtgggcgttttgtggacaggctgttacggattc ggcgttctccgaatcgccgggggctgtcatagtcctggcaggggggacgcaacgcgccaatccggtacggagcgcgcgggtccccgatgtc atccatgaccgcaggggggcggcg-3’;
[0063] SEQ ID No.6:
[0064]
[0065] In the present invention, the starting vector preferably includes a pSET152 vector; the recombinant gene preferably includes any one of 1) to 7), specifically:
[0066] 1) Psco7677 promoter, ypcc-1 gene and ypcc-2 gene linked in sequence from 5' to 3' direction;
[0067] 2) Pkasop* promoter, ypcc-1 gene and ypcc-2 gene connected in sequence from 5' to 3' direction;
[0068] 3) Ppkn5 promoter, ypcc-1 gene and ypcc-2 gene connected in sequence from 5' to 3' direction;
[0069] 4) Psco7677 promoter and yccr gene linked sequentially in the 5' to 3' direction;
[0070] 5) Pkasop* promoter and yccr gene linked sequentially from 5' to 3' end;
[0071] 6) Ppkn5 promoter and yccr gene linked sequentially in the 5' to 3' direction;
[0072] 7) Psco7677 promoter, ypcc-1 gene, ypcc-2 gene, Pkasop* promoter and yccr gene are sequentially connected from 5' to 3' end.
[0073] In the present invention, when the recombinant gene is any one of 1) to 6), the recombinant gene is preferably located between the BamH I and Xba I restriction sites of the pSET152 vector; when the recombinant gene is 7), the recombinant gene is preferably located between the BamH I and EcoR I restriction sites of the pSET152 vector.
[0074] The recombinant vector provided by the present invention heterologously overexpresses the pcc gene and / or ccr gene of Streptomyces albus into Streptomyces cinnamomi through a suitable promoter, and transforms the Streptomyces cinnamomi at the gene level, so that the transformed Streptomyces cinnamomi overexpresses the synthetic precursors (methylmalonyl CoA and ethylmalonyl CoA) of monensin, and the yield of monensin can be increased without increasing the supply of the precursors, thereby reducing the production cost and improving the production efficiency.
[0075] The present invention provides a primer set for constructing the recombinant vector described in the above technical solution, wherein the primer set includes one or more of the first primer set to the seventh primer set, specifically:
[0076] The first primer set included: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, and ypcc1-Psco7677-R;
[0077] The second primer set included: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Pkasop*-F, and ypcc1-Pkasop*-R;
[0078] The third primer set includes: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Ppkn5-F and ypcc1-Ppkn5-R;
[0079] The fourth primer set includes: yccr-F, 152-yccr-R, 152-Psco7677-F and yccr-Psco7677-R;
[0080] The fifth primer set includes: yccr-F, 152-yccr-R, 152-Pkasop*-F and yccr-Pkasop*-R;
[0081] The sixth primer set includes: yccr-F, 152-yccr-R, 152-Ppkn5-F and yccr-Ppkn5-R;
[0082] The seventh primer set includes: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, ypcc1-Psco7677-R, yccr-F, 152-yccr-R, 152-Pkasop*-F, yccr-Pkasop*-R, Pkasop*-yccr-F and Pkasop*-yccr-R;
[0083] The nucleotide sequences of the ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, ypcc1-Psco7677-R, 152-Pkasop*-F, ypcc1-Pkasop*-R, 152-Ppkn5-F, ypcc1-Ppkn5-R, yccr-F, 152-yccr-R, Pkasop*-yccr-F, Pkasop*-yccr-R, yccr-Psco7677-R, yccr-Pkasop*-R and yccr-Ppkn5-R are shown in SEQ ID No.7 to SEQ ID No.23 respectively.
[0084] The present invention provides a method for constructing the recombinant vector described in the above technical solution using the primer set described in the above technical solution, comprising the following steps:
[0085] Using the sequence shown in SEQ ID No. 1 as a template and ypcc1-F and ypcc1-R as primers, PCR amplification was performed to obtain the ypcc1 fragment;
[0086] Using the sequence shown in SEQ ID No. 2 as a template and ypcc2-F and 152-ypcc2-R as primers, PCR amplification was performed to obtain the ypcc2 fragment;
[0087] Using the sequence shown in SEQ ID No. 3 as a template and 152-Psco7677-F and ypcc1-Psco7677-R as primers, PCR amplification was performed to obtain the first Psco7677 fragment;
[0088] Using the sequence shown in SEQ ID No. 4 as a template and 152-Pkasop*-F and ypcc1-Pkasop*-R as primers, PCR amplification was performed to obtain the first Pkasop* fragment;
[0089] Using the sequence shown in SEQ ID No. 5 as a template and 152-Ppkn5-F and ypcc1-Ppkn5-R as primers, PCR amplification was performed to obtain the first Ppkn5 fragment;
[0090] Using the sequence shown in SEQ ID No. 3 as a template and 152-Psco7677-F and yccr-Psco7677-R as primers, PCR amplification was performed to obtain a second Psco7677 fragment;
[0091] Using the sequence shown in SEQ ID No. 4 as a template and 152-Pkasop*-F and yccr-Pkasop*-R as primers, PCR amplification was performed to obtain a second Pkasop* fragment;
[0092] Using the sequence shown in SEQ ID No. 5 as a template and 152-Ppkn5-F and yccr-Ppkn5-R as primers, PCR amplification was performed to obtain a second Ppkn5 fragment;
[0093] Using the sequence shown in SEQ ID No. 6 as a template and yccr-F and 152-yccr-R as primers, PCR amplification was performed to obtain the yccr fragment;
[0094] The first Psco7677 fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a first recombinant vector;
[0095] The first Pkasop* fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a second recombinant vector;
[0096] The first Ppkn5 fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a third recombinant vector;
[0097] The second Psco7677 fragment and the yccr fragment are inserted into the starting vector using the Gibson assembly method to obtain a fourth recombinant vector;
[0098] The second Pkasop* fragment and the yccr fragment are inserted into the starting vector by using the Gibson assembly method to obtain a fifth recombinant vector;
[0099] The second Ppkn5 fragment and the yccr fragment are inserted into the starting vector by using the Gibson assembly method to obtain a sixth recombinant vector;
[0100] The Psco7677 fragment, the ypcc1 fragment, the ypcc2 fragment, the Pkasop* fragment and the yccr fragment were inserted into the starting vector using the Gibson assembly method to obtain the seventh recombinant vector.
[0101] In the present invention, the construction method of the seventh recombinant vector is preferably: using the fifth recombinant vector as a template, using Pkasop*-yccr-F and Pkasop*-yccr-R as primers, amplifying to obtain the Pkasop*-yccr fragment; and inserting the Pkasop*-yccr fragment between the BamH I and EcoR I restriction sites of the first recombinant vector by the Gibson assembly method to obtain the seventh recombinant vector.
[0102] The present invention provides an engineered bacterium, the engineered bacterium comprising: the recombinant vector described in the above technical solution or the recombinant vector constructed using the primer set described in the above technical solution or the recombinant vector constructed using the method described in the above technical solution. In the present invention, the starting strain of the engineered bacterium preferably includes Streptomyces cinnamomi, and more preferably includes Streptomyces cinnamomi ATCC12308. The Streptomyces cinnamomi ATCC 12308 described in the present invention is a strain preserved by the American Type Culture Collection (ATCC), and is a commercially available strain, and the commercial channels preferably include Testos Bio (www.testobio.com, item number TS360559). The monensin yield of the engineered bacterium provided by the present invention reaches 3.26-4.05 g / L, which is 11%-38% higher than the starting strain into which the empty vector is transferred.
[0103] The present invention provides the use of the recombinant vector described in the above technical solution, or the recombinant vector constructed using the primer set described in the above technical solution, or the recombinant vector constructed using the method described in the above technical solution, or the recombinant bacteria described in the above technical solution in improving the yield of monensin.
[0104] To further illustrate the present invention, a recombinant vector, primer set, construction method, engineered bacteria and application for improving monensin production provided by the present invention are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0105] Example 1 Construction and titer detection of engineered bacteria B1 to B3
[0106] The engineered bacteria B1 to B3 were obtained by overexpressing pSET152-Psco7677-ypcc, pSET152-Pkasop*-ypcc and pSET152-Ppkn5-ypcc respectively, with Streptomyces cinnamonensis ATCC 12308 (denoted as B-1) as the starting strain. The specific construction methods are as follows:
[0107] (1) PCR amplification and recovery
[0108] Using the artificially synthesized sequence shown in SEQ ID No. 1 (ypcc-1) as a template and ypcc1-F and ypcc1-R as primers, PCR amplification was performed to obtain the ypcc1 fragment;
[0109] Using the artificially synthesized sequence shown in SEQ ID No. 2 (ypcc-2) as a template and ypcc2-F and 152-ypcc2-R as primers, PCR amplification was performed to obtain the ypcc2 fragment;
[0110] Using the artificially synthesized sequence shown in SEQ ID No. 3 (psco7677) as a template, PCR amplification was performed using 152-Psco7677-F and ypcc1-Psco7677-R as primers to obtain the Psco7677 fragment;
[0111] Using the artificially synthesized sequence shown in SEQ ID No. 4 (Pkasop*) as a template and 152-Pkasop*-F and ypcc1-Pkasop*-R as primers, PCR amplification was performed to obtain the Pkasop* fragment;
[0112] Using the artificially synthesized sequence shown in SEQ ID No. 5 (ppkn5) as a template and 152-Ppkn5-F and ypcc1-Ppkn5-R as primers, PCR amplification was performed to obtain the Ppkn5 fragment; the primer sequences are shown in Table 1.
[0113] Table 1 Nucleotide sequences of primers
[0114]
[0115] The reaction conditions of the PCR amplification are: pre-denaturation at 98°C for 5 min; denaturation at 98°C for 10 s, annealing at 67°C for 15 s, extension at 72°C for 25 s, 30 cycles; final extension at 72°C for 5 to 10 min; the reaction system of the PCR amplification is: 2×Primer star Maxbuffer 25 μL, forward primer (10 μM) 1.5 μL, reverse primer (10 μM) 1.5 μL, template 50 ng, and ddH2O supplemented to 50 μL.
[0116] After the PCR reaction is completed, the reaction product is subjected to agarose gel electrophoresis, irradiated under ultraviolet light and the gel block containing the target band is cut out. After the gel block is weighed, the DNA gel is recovered according to the instructions of the kit (TIANGEN ordinary agarose gel DNA recovery kit). After the recovery is completed, the DNA concentration is measured and stored at -20℃ for future use.
[0117] (2) Vector digestion and recovery
[0118] The pSET152 vector was double-digested with XbaI and BamHI; the double-digestion system was: 10×Buffer 4μL, XbaI 2μL, BamHI 2μL, pSET152 2μg, and ddH2O was added to 40μL; the reaction conditions of the double-digestion were: 37°C, 30min.
[0119] After the enzyme digestion, run the gel to determine the band size (the vector is about 5.7 kb); follow the instructions of the kit (TIANGEN ordinary agarose gel DNA recovery kit) to recover the DNA gel and obtain the linearized pSET152 vector (referred to as pSET152-BX). After recovery, measure the DNA concentration and store at -20°C for future use.
[0120] (3) Gibson assembly
[0121] The pSET152-BX and the Psco7677, ypcc1, and ypcc2 fragments obtained in step (1) were subjected to a Gibson assembly reaction using 2×Easy GenoMix to obtain a pSET152-Psco7677-ypcc recombinant vector; the reaction conditions were 50° C., 15 min; the reaction system was: Easy Geno Mix 5 μL, pSET152-BX 2 μL (0.02 pmol), Psco7677 0.5 μL (0.04 pmol), ypcc1 1.2 μL (0.04 pmol), and ypcc2 1.3 μL (0.04 pmol).
[0122] The pSET152-BX and the Pkasop*, ypcc1, and ypcc2 fragments obtained in step (1) were subjected to a Gibson assembly reaction using 2×Easy GenoMix to obtain a pSET152-Pkasop*-ypcc recombinant vector; the reaction conditions were 50° C., 15 min; the reaction system was: Easy Geno Mix 5 μL, pSET152-BX 2 μL (0.02 pmol), Pkasop* 0.5 μL (0.04 pmol), ypcc1 1.2 μL (0.04 pmol), and ypcc2 1.3 μL (0.04 pmol).
[0123] The pSET152-BX and Ppkn5, ypcc1, and ypcc2 obtained in step (1) were subjected to Gibson assembly reaction using 2×Easy Geno Mix to obtain a pSET152-Ppkn5-ypcc recombinant vector; the reaction conditions were 50° C., 15 min; the reaction system was: Easy Geno Mix 5 μL, pSET152-BX 2 μL (0.02 pmol), Ppkn5 0.5 μL (0.04 pmol), ypcc1 1.2 μL (0.04 pmol), and ypcc2 1.3 μL (0.04 pmol).
[0124] (4) Bacterial transformation and colony PCR identification
[0125] Take out the DH5α competent cells from the -80℃ refrigerator and place them on ice. After natural thawing, add the three reaction products obtained in step (3) (pSET152-Psco7677-ypcc, pSET152-Pkasop*-ypcc and pSET152-Ppkn5-ypcc recombinant vectors) respectively and mix gently. After standing on ice for 30 minutes, heat shock in a 42℃ water bath for 1 minute, and then stand on ice for 2 minutes. Add 500μL of antibiotic-free LB liquid culture medium to the clean bench and incubate at 37℃ for 30 minutes. Centrifuge at 3000rpm for 5 minutes at room temperature, discard most of the supernatant, retain 100μL of the supernatant to resuspend the bacteria, and spread it on the LB plate of the corresponding resistance, and invert and culture at 37℃ for 24 hours. When several monoclonal clones of appropriate size are grown, take them out for colony PCR identification, and streak the monoclonal plate for seed preservation. The recombinant vectors pSET152-Psco7677-ypcc, pSET152-Pkasop*-ypcc and pSET152-Ppkn5-ypcc were identified using the primers ypcc1-F and ypcc1R in Table 1. After the PCR reaction, agarose gel electrophoresis was performed, photographed under ultraviolet light, and positive colonies were determined based on the recorded electrophoresis patterns.
[0126] (5) Plasmid extraction and enzyme digestion verification
[0127] The above positive transformants were selected and cultured overnight in LB medium. 6 mL of overnight cultured bacterial solution was collected by centrifugation in a 2 mL centrifuge tube. Plasmids were extracted according to the instructions of the kit (TIANGEN plasmid mini-extraction kit). After double restriction digestion with Xba I and EcoR I, the restriction fragments were about 5.7 kb and 3.7 kb, which was verified to be correct. Sequencing was further used to verify whether the required plasmid was constructed correctly.
[0128] (6) ET bacteria transformation and hyphal conjugation transfer
[0129] The recombinant vectors pSET152-Psco7677-ypcc, pSET152-Pkasop*-ypcc and pSET152-Ppkn5-ypcc were respectively transformed into ET12567 (pUZ8002) competent cells, and the transformation method was the same as step (4), to obtain three types of ET bacteria containing the recombinant vectors.
[0130] The three ET bacterial colonies containing the recombinant vector were picked from the plate and transferred to 5 mL of LB liquid medium containing apramycin (Apr, 50 μg / mL), chloramphenicol (cm, 25 μg / mL) and kanamycin (kana, 50 μg / mL), and cultured at 37°C, 220 rpm, overnight. The overnight bacteria were transferred to LB liquid medium containing apramycin (Apr, 50 μg / mL), chloramphenicol (cm, 25 μg / mL) and kanamycin (kana, 50 μg / mL) at a ratio of 1:100, and cultured at 37°C, 220 rpm until the OD 600 When the p-value was 0.4, 10 mL of bacterial solution was collected in a centrifuge tube, centrifuged at 5000 rpm for 2 min, washed twice with 20 mL 2×YT (10 g / L tryptone, 5 g / L yeast extract and 10 g / L sodium chloride), and resuspended with 500 μL 2×YT to obtain three donor bacteria containing the recombinant vectors pSET152-Psco7677-ypcc, pSET152-Pkasop*-ypcc and pSET152-Ppkn5-ypc.
[0131] Take an appropriate amount of spores of Streptomyces cinnamomi ATCC 12308 from the glycerol tube and suspend them in a shake flask containing 30 mL of TSB liquid culture medium. Culture them at 30°C and 220 rpm. After culturing for 30 h, take 10 mL of them into a centrifuge tube, centrifuge them at 8000 rpm for 2 min, wash them twice with 20 mL of 2×YT, and resuspend them with 2 to 4 mL of 2×YT to obtain the recipient bacterial solution.
[0132] Pipette 100 μL of the recipient bacterial solution into the centrifuge tube where the donor bacteria were resuspended, mix thoroughly, spread on a plate covered with ISP4 medium, and culture at 30°C for 16 h.
[0133] Take out the plate from the incubator and cover it with 1 mL of sterile water containing Apr (50 μg / mL), sodium nalidixic acid (25 μg / mL) and a final concentration of 10 mM MgCl2. Blow dry on a clean bench, rotate the plate once every 15 to 30 minutes, and put it back into the incubator to continue culturing after it is completely blown dry.
[0134] (7) Identification of engineered bacteria
[0135] After 5 to 7 days, single colony conjugates can be seen growing on the plate. The conjugates are verified by mycelial PCR and resistance verification methods; primers apr-F and apr-R in Table 1 are used for PCR verification, the fragment length is 741 bp, the system and steps are shown in (4), where the annealing temperature is 65°C and the extension time is 1 min. The results are shown in Figure 1As shown, it can be seen that the target gene was successfully inserted into the strain in this example. The engineered bacteria containing the recombinant vector pSET152-Psco7677-ypcc was marked as B1, the engineered bacteria containing the recombinant vector pSET152-Pkasop*-ypcc was marked as B2, and the engineered bacteria containing the recombinant vector pSET152-Ppkn5-ypc was marked as B3.
[0136] After obtaining the engineered bacteria, the engineered bacteria are expanded and tested for titer. The specific operations are as follows:
[0137] (8) Expansion and titer testing of engineered bacteria
[0138] After verification, the correct engineered bacteria B1-B3, the empty control strain (only the pSET152 empty vector was transferred, without the target gene sequence, named B0) and the original strain B-1 were inoculated on the MN-PI solid medium, cultured at 30°C for 7 days, and a spore of about 1 square centimeter was dug and inoculated in the cinnamon Streptomyces seed medium, cultured at 30°C, 220rpm, and cultured for 30h. Then, with an inoculum amount of 8%, it was inoculated in the cinnamon Streptomyces fermentation medium, cultured at 30°C, 220rpm, and cultured for 10 days, and the fermentation broths of strains B0, B1, B2, B3 and B-1 were obtained respectively.
[0139] The formula of the MN-PI culture medium is as follows: 20 g soluble starch, 5 g cold-pressed soybean cake powder, 5 g maltodextrin, 1 g MgSO4, 0.5 g NaCl, 0.5 g K2HPO4, 0.02 g FeSO4, 1 g CaCO3, 24 g agar powder, and purified water to 1 L, pH = 7.0.
[0140] The formula of the seed culture medium is as follows: 5 g glucose, 20 g maltodextrin, 15 g cold-pressed soybean cake powder, 1 g MgSO4, 1 g K2HPO4, 4 g CaCO3, and purified water to 1 L, pH = 7.2.
[0141] The formula of the fermentation medium is as follows: 40 g glucose, 15 g cold-pressed soybean cake powder, 10 g yeast powder, 25 g soybean oil, 1 g K2HPO4, 0.5 g MgSO4, 0.2 g FeSO4, 4 g CaCO3, and tap water to 1 L, pH = 7.2.
[0142] The potency test method of monensin is as follows: take 0.5 ml of fermentation liquid, centrifuge and discard the supernatant, then extract with 4.5 ml of methanol, ultrasonicate for 20 minutes, centrifuge and take the supernatant, filter through a 0.22 μm organic filter membrane for HPLC detection. HPLC analysis conditions, chromatographic column: Shimadzu C18 column (4.6 mm × 150 mm, 5 μm); evaporative light scattering detector; mobile phase is pure methanol and 20 mM ammonium acetate solution, according to the first 25 minutes, the content of chromatographic methanol is from 80% to 100%, and the content of chromatographic methanol is from 100% to 80% in the last 5 minutes for gradient elution, and the mobile phase flow rate is 1 mL / min. Results are shown in Figure 2 and Table 2.
[0143] Table 2 Fermentation yields of monensin from different strains
[0144] serial number Monensin yield (g / L) B-1 2.91 B0 2.93 B1 3.49 B2 3.37 B3 3.26
[0145] The results showed that the yields of the three engineered bacteria B1 to B3 constructed by the present invention were all increased to varying degrees, among which the yield of the B1 engineered bacteria was the most significantly increased, with a yield increase of 19% compared with the empty control, and the final yield of monensin in shake flask fermentation reaching 3.49 g / L; in addition, the yield of the B2 engineered bacteria increased by 15%, reaching a final yield of 3.37 g / L, and the yield of the B3 engineered bacteria increased by 11%, reaching a final yield of 3.26 g / L. This shows that overexpression of the ypcc gene has a positive significance for increasing the yield of monensin, and the ypcc gene tandem with the Psco7677 promoter has the best effect.
[0146] Example 2 Construction and titer detection of engineered bacteria B4-B6
[0147] The engineered bacteria B4 to B6 were obtained by overexpressing pSET152-Psco7677-yccr, pSET152-Pkasop*-yccr and pSET152-Ppkn5-yccr respectively, with Streptomyces cinnamomi ATCC 12308 (denoted as B-1) as the starting strain. The specific construction method is as follows:
[0148] 1) PCR amplification and recovery
[0149] Using the artificially synthesized sequence (yccr) shown in SEQ ID No.6 as a template and yccr-F and 152-yccr-R in Table 1 as primers, PCR amplification was performed to obtain the yccr fragment; the method was referred to step (1) in Example 1; amplification of Psco7677, Pkasop* and Ppkn5 fragments was performed using a method similar to step (1) in Example 1, except that the primers ypcc1-Psco7677-R, ypcc1-Pkasop*-R and ypcc1-Ppkn5-R were replaced by yccr-Psco7677-R, yccr--Pkasop*-R and yccr--Ppkn5-R in Table 1, respectively;
[0150] 2) The vector was digested and recovered in the same manner as step (2) in Example 1.
[0151] 3) Fragment assembly, transformation and identification
[0152] pSET152-BX, Psco7677, and yccr were assembled, transformed, colony identified, plasmid extracted, enzyme digestion verified, and sequenced to obtain the recombinant vector pSET152-Psco7677-yccr. The specific method was the same as steps (3), (4), and (5) in Example 1, wherein the primers for colony identification were yccr-F and 152-yccr-R in Table 1.
[0153] pSET152-BX, Pkasop*, and yccr were assembled, transformed, colony identified, plasmid extracted, enzyme digestion verified, and sequenced to obtain the recombinant vector pSET152-Pkasop*-yccr. The specific method is as shown in steps (3), (4), and (5) in Example 1, wherein the primers for colony identification are yccr-F and 152-yccr-R in Table 1.
[0154] pSET152-BX, Ppkn5, and yccr were assembled, transformed, colony identified, plasmid extracted, enzyme digestion verified, and sequenced to obtain the recombinant vector pSET152-Ppkn5-yccr. The specific method is as shown in steps (3), (4), and (5) in Example 1, wherein the primers for colony identification are yccr-F and 152-yccr-R in Table 1.
[0155] 4) ET bacteria transformation and hyphal conjugation transfer
[0156] The recombinant vectors pSET152-Psco7677-yccr, pSET152-Pkasop*-yccr and pSET152-Ppkn5-yccr were respectively transferred into ET12567 / pUZ8002, and then introduced into the starting strain B-1 by conjugation transfer method. The specific method is shown in step (6) of Example 1.
[0157] 5) Identification, expansion and titer testing of engineered bacteria
[0158] The results of engineering bacteria identification are shown in Figure 1 It can be seen that the target gene was successfully inserted into the strain in this example. The engineered bacteria containing the recombinant vector pSET152-Psco7677-yccr were marked as B4, the engineered bacteria containing the recombinant vector pSET152-Pkasop*-yccr were marked as B5, and the engineered bacteria containing the recombinant vector pSET152-Ppkn5-yccr were marked as B6.
[0159] After verification, the correct engineered bacteria B4-B6, the empty control strain (only the pSET152 empty vector was transferred, without the target gene sequence, named B0) and the starting strain B-1 were fermented and verified. The specific method is as shown in steps (7) and (8) of Example 1. The results are shown in Figure 2 and Table 3.
[0160] Table 3 Fermentation yields of monensin from different strains
[0161] serial number Monensin yield (g / L) B-1 2.91 B0 2.93 B4 3.43 B5 3.66 B6 3.40
[0162] The results showed that the yields of the three engineered bacteria screened by the present invention were all increased to varying degrees, among which the yield of the B5 engineered bacteria was the most significantly increased, with a yield increase of 25% compared with the empty control, and the final yield of monensin in laboratory shake flask fermentation reached 3.66 g / L; in addition, the yield of the B4 engineered bacteria increased by 17%, reaching a final yield of 3.43 g / L, and the yield of the B6 engineered bacteria increased by 16%, reaching a final yield of 3.40 g / L. This shows that overexpression of the ypcc gene has a positive significance for increasing the yield of monensin, and the yccr gene tandem with the Pkasop* promoter has the best effect.
[0163] Example 3 Construction and titer detection of engineered bacteria B7
[0164] The engineered strain B7 was obtained by overexpressing pSET152-Psco7677-ypcc-Pkasop*-yccr with Streptomyces cinnamomi ATCC 12308 (denoted as B-1) as the starting strain. The specific construction method is as follows:
[0165] 1) PCR amplification and recovery
[0166] The recombinant vector pSET152-Pkasop*-yccr constructed in Example 2 was used as a template, and Pkasop*-yccr-F and Pkasop*-yccr-R were used as primers to amplify the Pkasop*-yccr fragment. Before recovery, the template plasmid was digested with DpnI. The specific method is as shown in step (1) of Example 1.
[0167] 2) Vector digestion and recovery
[0168] The recombinant vector pSET152-Psco7677-ypcc constructed in Example 1 was treated with BamH I and EcoR I for double digestion, and the pSET152-Psco7677-ypcc-BE fragment was obtained by gel recovery. The specific method is as shown in step (2) of Example 1.
[0169] 3) Fragment assembly, transformation and identification
[0170] pSET152-ppsco7677-ypcc-BE and Pkasop*-yccr were assembled, transformed, colony identified, plasmid extracted, enzyme digestion verified and sequenced to obtain the recombinant vector pSET152-Psco7677-ypcc-Pkasop*-yccr. The specific method is as shown in steps (3), (4) and (5) in Example 1, wherein the primers for colony identification are yccr-F and 152-yccr-R in Table 1.
[0171] 4) ET bacteria transformation and hyphal conjugation transfer
[0172] The recombinant vector pSET152-Psco7677-ypcc-Pkasop*-yccr was transferred into ET12567 / pUZ8002, and then introduced into the starting strain B-1 by conjugation transfer method. The specific method is shown in step (6) of Example 1.
[0173] 5) Identification, expansion and titer testing of engineered bacteria
[0174] The results of engineering bacteria identification are as follows Figure 1 As shown, it can be seen that the target gene was successfully inserted into the strain in this example, and the strain containing the recombinant vector pSET152-Psco7677-ypcc-Pkasop*-yccr was named B7. After verification, the correct engineered bacteria B7, the empty control strain (only the pSET152 empty vector was transferred, without the target gene sequence, named B0) and the starting strain B-1 were fermented for verification. The specific method is as shown in steps (7) and (8) of Example 1. The results are shown in Figure 2 and Table 4.
[0175] Table 4 Fermentation yield of monensin from different strains
[0176] serial number Monensin yield (g / L) B-1 2.91 B0 2.93 B7 4.05
[0177] The results showed that the yield of B7 engineered bacteria screened by the present invention was greatly improved, the yield of B7 engineered bacteria increased by 38%, and the final yield reached 4.05 g / L. This showed that tandem overexpression of Psco7677-ypcc and Pkasop*-ycc genes had a positive effect on improving the potency of monensin.
[0178] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A recombinant vector for increasing the yield of monensin, It is characterized in that It comprises a starting vector and a recombinant gene inserted into the starting vector; the recombinant gene comprises a target gene and a promoter; the target gene comprises a ypcc gene and / or a yccr gene; the ypcc gene comprises a ypcc-1 gene and a ypcc-2 gene; the promoter comprises one or more of a Psco7677 promoter, a Pkasop* promoter and a Ppkn5 promoter; the nucleotide sequence of the ypcc-1 gene is shown in SEQ ID No.1; the nucleotide sequence of the ypcc-2 gene is shown in SEQ ID No.2; the nucleotide sequence of the Psco7677 promoter is shown in SEQ ID No.3; the nucleotide sequence of the Pkasop* promoter is shown in SEQ ID No.4; the nucleotide sequence of the Ppkn5 promoter is shown in SEQ ID No.5; the nucleotide sequence of the yccr gene is shown in SEQ ID No.
6.
2. The recombinant vector according to claim 1, It is characterized in that The starting vector includes the pSET152 vector.
3. The recombinant vector according to claim 1 or 2, It is characterized in that The recombinant gene includes any one of 1) to 7), specifically: 1) Psco7677 promoter, ypcc-1 gene and ypcc-2 gene linked in sequence from 5' to 3' direction; 2) Pkasop* promoter, ypcc-1 gene and ypcc-2 gene connected in sequence from 5' to 3' direction; 3) Ppkn5 promoter, ypcc-1 gene and ypcc-2 gene connected in sequence from 5' to 3' direction; 4) Psco7677 promoter and yccr gene linked sequentially in the 5' to 3' direction; 5) Pkasop* promoter and yccr gene linked sequentially from 5' to 3' end; 6) Ppkn5 promoter and yccr gene linked sequentially in the 5' to 3' direction; 7) Psco7677 promoter, ypcc-1 gene, ypcc-2 gene, Pkasop* promoter and yccr gene are sequentially connected from 5' to 3' end.
4. The recombinant vector according to claim 3, It is characterized in that When the recombinant gene is any one of 1) to 6), the recombinant gene is located between the BamH I and Xba I restriction sites of the pSET152 vector; when the recombinant gene is 7), the recombinant gene is located between the BamH I and EcoR I restriction sites of the pSET152 vector.
5. A primer set for constructing the recombinant vector according to any one of claims 1 to 4, It is characterized in that The primer set includes one or more of the first primer set to the seventh primer set, specifically: The first primer set included: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, and ypcc1-Psco7677-R; The second primer set included: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Pkasop*-F, and ypcc1-Pkasop*-R; The third primer set includes: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Ppkn5-F and ypcc1-Ppkn5-R; The fourth primer set includes: yccr-F, 152-yccr-R, 152-Psco7677-F and yccr-Psco7677-R; The fifth primer set includes: yccr-F, 152-yccr-R, 152-Pkasop*-F and yccr-Pkasop*-R; The sixth primer set includes: yccr-F, 152-yccr-R, 152-Ppkn5-F and yccr-Ppkn5-R; The seventh primer set includes: ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, ypcc1-Psco7677-R, yccr-F, 152-yccr-R, 152-Pkasop*-F, yccr-Pkasop*-R, Pkasop*-yccr-F and Pkasop*-yccr-R; The nucleotide sequences of the ypcc1-F, ypcc1-R, ypcc2-F, 152-ypcc2-R, 152-Psco7677-F, ypcc1-Psco7677-R, 152-Pkasop*-F, ypcc1-Pkasop*-R, 152-Ppkn5-F, ypcc1-Ppkn5-R, yccr-F, 152-yccr-R, Pkasop*-yccr-F, Pkasop*-yccr-R, yccr-Psco7677-R, yccr-Pkasop*-R and yccr-Ppkn5-R are shown in SEQ ID No.7 to SEQ ID No.23 respectively.
6. A method for constructing the recombinant vector according to any one of claims 1 to 4 using the primer set according to claim 5, It is characterized in that The following steps are involved: Using the sequence shown in SEQ ID No. 1 as a template and ypcc1-F and ypcc1-R as primers, PCR amplification was performed to obtain the ypcc1 fragment; Using the sequence shown in SEQ ID No. 2 as a template and ypcc2-F and 152-ypcc2-R as primers, PCR amplification was performed to obtain the ypcc2 fragment; Using the sequence shown in SEQ ID No. 3 as a template and 152-Psco7677-F and ypcc1-Psco7677-R as primers, PCR amplification was performed to obtain the first Psco7677 fragment; Using the sequence shown in SEQ ID No. 4 as a template and 152-Pkasop*-F and ypcc1-Pkasop*-R as primers, PCR amplification was performed to obtain the first Pkasop* fragment; Using the sequence shown in SEQ ID No. 5 as a template and 152-Ppkn5-F and ypcc1-Ppkn5-R as primers, PCR amplification was performed to obtain the first Ppkn5 fragment; Using the sequence shown in SEQ ID No. 3 as a template and 152-Psco7677-F and yccr-Psco7677-R as primers, PCR amplification was performed to obtain a second Psco7677 fragment; Using the sequence shown in SEQ ID No. 4 as a template and 152-Pkasop*-F and yccr-Pkasop*-R as primers, PCR amplification was performed to obtain a second Pkasop* fragment; Using the sequence shown in SEQ ID No. 5 as a template and 152-Ppkn5-F and yccr-Ppkn5-R as primers, PCR amplification was performed to obtain a second Ppkn5 fragment; Using the sequence shown in SEQ ID No. 6 as a template and yccr-F and 152-yccr-R as primers, PCR amplification was performed to obtain the yccr fragment; The first Psco7677 fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a first recombinant vector; The first Pkasop* fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a second recombinant vector; The first Ppkn5 fragment, the ypcc1 fragment and the ypcc2 fragment are inserted into the starting vector by using the Gibson assembly method to obtain a third recombinant vector; The second Psco7677 fragment and the yccr fragment are inserted into the starting vector using the Gibson assembly method to obtain a fourth recombinant vector; The second Pkasop* fragment and the yccr fragment are inserted into the starting vector by using the Gibson assembly method to obtain a fifth recombinant vector; The second Ppkn5 fragment and the yccr fragment are inserted into the starting vector by using the Gibson assembly method to obtain a sixth recombinant vector; The Psco7677 fragment, the ypcc1 fragment, the ypcc2 fragment, the Pkasop* fragment and the yccr fragment were inserted into the starting vector using the Gibson assembly method to obtain the seventh recombinant vector.
7. The method according to claim 6, It is characterized in that The construction method of the seventh recombinant vector is: using the fifth recombinant vector as a template, using Pkasop*-yccr-F and Pkasop*-yccr-R as primers, amplifying to obtain the Pkasop*-yccr fragment; using the Gibson assembly method to insert the Pkasop*-yccr fragment between the BamH I and EcoR I restriction sites of the first recombinant vector to obtain the seventh recombinant vector.
8. An engineered bacterium, It is characterized in that The engineered bacteria include: the recombinant vector according to any one of claims 1 to 4, or a recombinant vector constructed using the primer set according to claim 5, or a recombinant vector constructed using the method according to claim 6 or 7.
9. The engineered bacteria according to claim 9, It is characterized in that The starting strain of the engineering bacteria includes Streptomyces cinnamonensis.
10. Use of the recombinant vector according to any one of claims 1 to 4, or the recombinant vector constructed using the primer set according to claim 5, or the recombinant vector constructed using the method according to claim 6 or 7, or the recombinant bacterium according to claim 8 or 9 in increasing the yield of monensin.
Citation Information
Cited By
Gene for improving reducing power and producing monensin at high yield through multi-gene synergistic expression, vector and strain
CN121699952A
Recombinant cinnamon streptomyces and application thereof in monensin production
CN121718479A
